The biggest risk is what I call being "Contract rich, cashflow poor". We are a little exposed until consistent sales revenue overtakes lumpy one-off revenue.
My out of left field concerns are:
1. the factory catching fire
2. disgruntled ex-employees shooting up the place and
3. the FDA shutting down Hikma generics operations (I believe Hikma took market share in the USA when a competitor (Indian mob owned by Daichi Sankyo) got shut down by the FDA for poor quality standards).
I'm being serious here. I have a very active imagination. I suppose floods, pestilence and zombies also.
Add to My Watchlist
What is My Watchlist?